NLRP3 and colitis: On this basis, our experimental results demonstrated that isobutyric acid pretreatment effectively suppressed NLRP3 inflammasome overactivation and protected against colitis in murine models, mirroring the therapeutic effects observed with Lac16 administration as indicated by significant amelioration of clinical symptoms.